首页> 外文期刊>Journal of the American Chemical Society >Natural Products in the 'Marketplace': Interfacing Synthesis and Biology
【24h】

Natural Products in the 'Marketplace': Interfacing Synthesis and Biology

机译:“市场”中的天然产品:合成与生物学的接口

获取原文
获取原文并翻译 | 示例
           

摘要

Drugs are discovered through the biological screening of collections of compounds, followed by optimization toward functional end points. The properties of screening collections are often balanced between diversity, physicochemical favorability, intrinsic complexity, and synthetic tractability (Huggins, D. J.; et al. ACS Chem. Biol. 2011, 6, 208; DOI: 10.1021/cb100420r). Whereas natural product (NP) collections excel in the first three attributes, NPs suffer a disadvantage on the last point. Academic total synthesis research has worked to solve this problem by devising syntheses of NP leads, diversifying late-stage intermediates, or derivatizing the NP target. This work has led to the discovery of reaction mechanisms, the invention of new methods, and the development of FDA-approved drugs. Few drugs, however, are themselves NPs; instead, NP analogues predominate. Here we highlight past examples of NP analogue development and successful NP-derived drugs. More recently, chemists have explored how NP analogues alter the retrosynthetic analysis of complex scaffolds, merging structural design and synthetic design. This strategy maintains the intrinsic complexity of the NP but can alter the physicochemical properties of the scaffold, like core instability that renders the NP a poor chemotype. Focused libraries based on these syntheses may exclude the NP but maintain the molecular properties that distinguish NP space from synthetic space (Stratton, C. F.; et al. Bioorg. Med. Chem. Lett. 2015, 25, 4802; DOI: 10.1016/j.bmcl.2015.07.014), properties that have statistical advantages in clinical progression (Luker, T.; et al. Bioorg. Med. Chem. Lett. 2011, 21, 5673, DOI: 10.1016/j.bmcl.2011.07.074; Ritchie, T. J.; Macdonald, S. J. F. Drug Discovery Today 2009, 14, 1011, DOI: 10.1016/j.drudis.2009.07.014). Research that expedites synthetic access to NP motifs can prevent homogeneity of chemical matter available for lead discovery. Easily accessed, focused libraries of NP scaffolds can fill empty but active gaps in screening sets and expand the molecular diversity of synthetic collections.
机译:通过对化合物集合进行生物筛选,然后对功能终点进行优化来发现药物。筛选收集物的性质通常在多样性,物理化学上的亲和力,固有的复杂性和合成的可处理性之间达到平衡(Huggins,D.J .;等人ACS Chem.Biol.2011,6,208; DOI:10.1021 / cb100420r)。天然产品(NP)集合在前三个属性中表现出色,而NP在最后一点上则处于劣势。全面的学术研究致力于通过设计NP线索的合成,后期中间体的多样化或NP目标的衍生化来解决这个问题。这项工作导致了反应机理的发现,新方法的发明以及FDA批准药物的开发。然而,很少有药物本身就是NP。相反,NP类似物占主导地位。在这里,我们重点介绍NP类似物开发和成功的NP衍生药物的过去实例。最近,化学家们探索了NP类似物如何改变复杂支架的逆合成分析,融合结构设计和合成设计。这种策略保持了NP的内在复杂性,但可以改变支架的物理化学性质,例如使NP成为不良化学型的核心不稳定性。基于这些合成的聚焦文库可以排除NP,但保留将NP空间与合成空间区分开的分子特性(Stratton,CF; et al.Bioorg.Med.Chem.Lett.2015,25,4802; DOI:10.1016 / j。 bmcl.2015.07.014),在临床进展中具有统计学优势的特性(Luker,T .; et al。Bioorg。Med.Chem.Lett.2011,21,5673,DOI:10.1016 / j.bmcl.2011.07.074;田纳西州里奇(Ritchie);麦当劳(Macdonald),《 SJF今日药物发现》 2009年14月10日,DOI:10.1016 / j.drudis.2009.07.014加快对NP基序的合成访问的研究可以防止可用于铅发现的化学物质的均质性。易于访问的NP支架集中库可以填补筛选集中的空白,但仍能有效填补空白,并扩展了合成馆藏的分子多样性。

著录项

  • 来源
    《Journal of the American Chemical Society》 |2019年第8期|3332-3346|共15页
  • 作者单位

    Scripps Res Inst, Dept Chem, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA;

    Scripps Res Inst, Dept Chem, 10550 North Torrey Pines Rd, La Jolla, CA 92037 USA;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号